Literature DB >> 28249867

Obesity Paradox: Comparison of Heart Failure Patients With and Without Comorbid Diabetes.

Kyoung Suk Lee1, Debra K Moser2, Terry A Lennie2, Michele M Pelter2, Thomas Nesbitt2, Jeffrey A Southard2, Kathleen Dracup2.   

Abstract

BACKGROUND: Diabetes is a common comorbid condition in patients with heart failure and is strongly associated with poor outcomes. Patients with heart failure who have diabetes are more likely to be obese than are those without diabetes. Obesity is positively associated with survival in patients with heart failure, but how comorbid diabetes influences the relationship between obesity and favorable prognosis is unclear.
OBJECTIVE: To explore whether the relationship between body mass index and survival differs between patients with heart failure who do or do not have diabetes.
METHODS: The sample consisted of 560 ambulatory patients with heart failure (mean age, 66 years; mean body mass index, 32; diabetes, 41%). The association between body mass index and all-cause mortality was examined by using multivariate Cox proportional hazards regression after adjustments for covariates.
RESULTS: In patients without diabetes, higher body mass index was associated with a lower risk for all-cause mortality after adjustments for covariates (hazard ratio, 0.952; 95% CI, 0.909-0.998). In patients with diabetes, body mass index was not predictive of all-cause death after adjustments for covariates.
CONCLUSION: Obesity was a survival benefit in heart failure patients without comorbid diabetes but not in those with comorbid diabetes. The mechanisms underlying the difference in the relationship between obesity and survival due to the presence of diabetes in patients with heart failure need to be elucidated. ©2017 American Association of Critical-Care Nurses.

Entities:  

Mesh:

Year:  2017        PMID: 28249867     DOI: 10.4037/ajcc2017634

Source DB:  PubMed          Journal:  Am J Crit Care        ISSN: 1062-3264            Impact factor:   2.228


  7 in total

1.  THE ROLE OF NT PRO-BNP IN THE EVALUATION OF DIABETIC PATIENTS WITH HEART FAILURE.

Authors:  F I Fringu; A V Sitar-Taut; B Caloian; D Zdrenghea; D Comsa; G Gusetu; D Pop
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

2.  The health outcomes of inflammation and obesity in patients with heart failure.

Authors:  Zyad T Saleh; Terry A Lennie; Muhammad Darawad; Hamza Alduraidi; Rami A Elshatarat; Issa M Almansour; Debra K Moser
Journal:  Heart Lung       Date:  2020-06-05       Impact factor: 2.210

3.  Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017.

Authors:  Thomas R Einarson; Annabel Acs; Craig Ludwig; Ulrik H Panton
Journal:  Cardiovasc Diabetol       Date:  2018-06-08       Impact factor: 9.951

4.  Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study.

Authors:  B Zareini; Rasmus Rørth; Anders Holt; Ulrik M Mogensen; Christian Selmer; Gunnar Gislason; Morten Schou; Lars Køber; Christian Torp-Pedersen; Morten Lamberts; Søren Lund Kristensen
Journal:  Cardiovasc Diabetol       Date:  2019-06-12       Impact factor: 9.951

5.  Sex Differences in the Association Between Inflammation and Event-Free Survival in Patients With Heart Failure.

Authors:  Zyad T Saleh; Ahmad T Alraoush; Ahmad A Aqel; Tagreed O Shawashi; Misook Chung; Terry A Lennie
Journal:  J Cardiovasc Nurs       Date:  2021-07-06       Impact factor: 2.083

6.  Association between body mass index and survival in Taiwanese heart failure patients with and without diabetes mellitus.

Authors:  Yu Ying Lu; Victor Chien Chia Wu; Pao-Hsien Chu; Chien-Te Ho; Chieh-Yu Chang
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

7.  Obesity paradox among elderly patients with coronary artery disease undergoing non-cardiac surgery.

Authors:  Lu Che; Li Xu; Ming-Ya Wang; Yu-Guang Huang
Journal:  J Geriatr Cardiol       Date:  2018-09-28       Impact factor: 3.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.